|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Biologic agents for anterior cruciate ligament healing: a systematic review显示文摘AIM To systematically review the currently available literature concerning the application of biologic agents such as platelet-rich plasma(PRP) and stem cells to promote anterior cruciate ligament(ACL) healing.METHODS A systematic review of the literature was performed on the use of biologic agents(i.e., PRP or stem cells) to favor ACL healing during reconstruction or repair. The following inclusion criteria for relevant articles were used: Clinical reports of any level of evidence, written in English language, on the use of PRP or stem cells during ACL reconstruction/repair. Exclusion criteria were articles written in other languages, reviews, or studies analyzing other applications of PRP/stem cells in knee surgery not related to promoting ACL healing.RESULTS The database search identified 394 records that were screened. A total of 23 studies were included in the final analysis: In one paper stem cells were applied for ACL healing, in one paper there was a concomitant application of PRP and stem cells, whereas in the remaining21 papers PRP was used. Based on the ACL injury pattern, two papers investigated biologic agents in ACL partial tears whereas 21 papers in ACL reconstruction.Looking at the quality of the available literature, 17 out of 21 studies dealing with ACL reconstruction were randomized controlled trials. Both studies on ACL repair were case series.CONCLUSION There is a paucity of clinical trials investigating the role of stem cells in promoting ACL healing both in case of partial and complete tears. The role of PRP is still controversial and the only advantage emerging from the literature is related to a better graft maturation over time, without documenting beneficial effects in terms of clinical outcome, bone-graft integration and prevention of bony tunnel enlargement. | Berardo Di Matteo Markus Loibl Luca Andriolo Giuseppe Filardo Johannes Zellner Matthias Koch Peter Angele | 2016 | World Journal of Orthopedics2016，7，9： | 3 |
| 2 | The role of early expression of inducible nitric oxide synthase in human breast cancer 显示文摘 | Loibl S Buck A Strank C | 2005 | Eur J Cancer2005，41，2： | 1 |
| 3 | Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy(GeparQuinto,GBG 44):a randomised phase 3 trial显示文摘 | Untch M Loibl S Bischoff J | 2012 | Lancet Oncol2012，13，2： | 1 |
| 4 | Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial显示文摘 | Untch M Loibl S Bischoff J | 2012 | Lancet Oncol2012，13，2： | 1 |
| 5 | Re-challenging taxanes in recurrentbreast cancer in patients treated with (Neo-) adjuvant taxane-basedtherapy 显示文摘 | Guo X Loibl S Untch M | 2011 | Breast Care (Basel)2011，6，4： | 1 |
| 6 | The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer显示文摘 | Cardoso F Loibl S Pagani O | 2012 | Eur J Cancer2012，48，18： | 1 |
| 7 | Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer 显示文摘 | Denkert C Loibl S Noske A | 2010 | J Clin Oneol2010，28，1： | 1 |
| 8 | Investor information search显示文摘 | Loibl C Hira T K | 2009 | Journal of Economic Psychology2009，30，1： | 1 |
| 9 | Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy显示文摘 | Lindner JL Loibl S Denkert C | 2015 | Ann Oncol2015，26，1： | 1 |
| 10 | Identification of biology- based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracyeline/taxane-based chemotherapy 显示文摘 | Darb ES Loibl S Roller M | 2009 | Breast cancer research2009，11，5： | 1 |
| 11 | Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer显示文摘 | Denkert C Loibl S Noske A | | 0，，01： | 1 |
| 12 | Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy-a translational project of the German Breast Group study GeparQnattro显示文摘 | Miiller V Riethdorf S Loibl S | 2007 | J Clin Oncol2007，25，21： | 1 |
| 13 | Direct cell-cell contact between mesenchymal stem cells and endothelial progenitor ceils induces a pericyte-like phenotype in vitro 显示文摘 | Loibl M Binder A Herrmann M | 2014 | Biomed Res Int2014，2014，39： | 1 |
| 14 | Outcome after neoadjuvant chemotherapy in young breast cancer patients : a pooled analysis of individual patient data from eight prospectively randomized controlled trials 显示文摘 | Loibl S Jackisch C Lederer B | 2015 | Breast Cancer Res Treat2015，152，2： | 1 |
| 15 | Neoadjuvant car- boplatin in patients with triple-negative and HER2-positive early breast cancer( GeparSixto; GBG 66) : a randomised phase 2 trial 显示文摘 | von Minckwitz G Schneeweiss A Loibl S | 2014 | Lancet Oncol2014，15，7： | 1 |
| 16 | Ki67 measured after neoadjuvant chemotherapy for primary breast cancer显示文摘 | von Minckwitz G Schmitt WD Loibl S | 2013 | Clin Cancer Res2013，19，16： | 1 |
| 17 | The role of soluble and cell- surface expressed 4-1BB ligand in patients with malignant hemo- poietic disorders显示文摘 | Scholl N Loibl J Kremser A | 2009 | Leuk Lymphoma2009，50，3： | 1 |
| 18 | Capecitabine plus pa- clitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase Ⅲ trial by the AGO Breast Cancer Study Group 显示文摘 | Ltick HJ Du Bois A Loibl S | 2013 | Breast Cancer Res Treat2013，139，3： | 1 |
| 19 | Breast cancer in pregnancy显示文摘 | Amant F Loibl S Neven P | | 0，，： | 1 |
| 20 | Phase II muhicenter, un- controlled trial of sorafenib in patients with metastatic breast cancer 显示文摘 | Bianehi G Loibl S Zamagni C | 2009 | Anticancer Drugs2009，20，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员